MCMBP and cancer: Therefore, MCMBP is a potential target for cancer chemotherapy, to kill p53-deficient cancers by allowing them to enter the S phase with an insufficient number of licensed origins (McIntosh and Blow, 2012), whereas normal cells are temporarily arrested in the G0 or G1 phase.